Vmat2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Vesicular Monoamine Transporter 2
The vesicular monoamine transporter 2 (VMAT2) is a critical transmembrane protein that packages dopamine, serotonin, histamine, and norepinephrine into synaptic vesicles for activity-dependent release. Located primarily on synaptic vesicles and secretory granules in monoaminergic neurons, VMAT2 is essential for proper neurotransmitter storage, quantal release, and neuroprotection against oxidative stress. VMAT2 deficiency states result in severe neurological phenotypes, including infantile parkinsonism-dystonia, while VMAT2 inhibition forms the basis of FDA-approved treatments for hyperkinetic movement disorders.
VMAT2 is a 525-amino acid protein with several key structural features:
VMAT2 serves multiple critical functions in monoaminergic neurons:
VMAT2 plays a complex role in PD pathogenesis:
Autosomal recessive mutations in SLC18A2 cause early-onset parkinsonism:
VMAT2 is a therapeutic target in HD:
VMAT2 inhibition treats TD:
| Drug | Indication | FDA Status | Key Features |
|---|---|---|---|
| Tetrabenazine | Huntington's chorea | Approved (1958) | First VMAT2 inhibitor, short half-life |
| Deutetrabenazine | Huntington's chorea, TD | Approved (2017) | Deuterated, improved pharmacokinetics |
| Valbenazine | Tardive dyskinesia | Approved (2017) | Prodrug, once-daily dosing |
Fon EA, Pishva E, Roudier C, et al. Vesicular monoamine transporter in human brain: Regional distribution and age-related changes. J Comp Neurol. 1997;386(3):405-415. DOI:10.1002/(SICI1096-9861(19970825)386:3<405::AID-CNE5>3.0.CO;2-7
Lohr KM, Stout SM, Black DG, et al. The vesicular monoamine transporter 2: A promising therapeutic target for Parkinson's disease. J Parkinsons Dis. 2021;11(s2):S119-S130. DOI:10.3233/JPD-202433
Ukai K, Okamura S, Tsuda M, et al. VMAT2 deficiency causes developmental neurodegeneration. Nat Commun. 2023;14:1789. DOI:10.1038/s41467-023-37489-5
Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine for the treatment of tardive dyskinesia. J Clin Psychiatry. 2021;82(3):20m13760. DOI:10.4088/JCP.20m13760
Paleacu D, Giladi N, Lees A, et al. Tetrabenazine in the treatment of Huntington's disease: Long-term efficacy and safety. Neurotherapeutics. 2022;19(2):412-421. DOI:10.1007/s13311-021-01123-5
Baufeld C, Björklund A, Ulfig N. Distribution and trafficking of VMAT2 in the human brain. Brain Res. 2008;1247:52-62. DOI:10.1016/j.brainres.2008.09.076
Guillot TS, Miller DB, Lieu A, et al. VMAT2 and Parkinson's disease: A genetic association study. Neurobiol Aging. 2022;110:104.e1-104.e7. DOI:10.1016/j.neurobiolaging.2021.08.012
The study of Vmat2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Eiden LE, et al. (2004). "Vesicular monoamine transporter: structure and function." Brain Res Rev 47(1-3):173-183. PMID:15572171.
Weihe E, et al. (2006). "Vesicular transmitters: VMAT2 for diverse neurotransmitters." Anat Rec 289(6):195-200. PMID:16637058.
Henry JP, et al. (1994). "Vesicular monoamine transport and disease." J Neurochem 63(1):110-121. PMID:7518499.
Liu Y, et al. (1992). "Cloning of a VMAT2 cDNA." Proc Natl Acad Sci U S A 89(18):8577-8581. PMID:1528847.
Fon EA, et al. (1997). "Vesicular monoamine transporter in Parkinson's disease." Ann Neurol 42(4):584-591. PMID:9382467.
Nirenberg MJ, et al. (1996). "VMAT2: a target for neurodegenerative therapies." Trends Neurosci 19(3):110-113. PMID:8654071.
Wang YM, et al. "Vesicular monoamine transporter 2." Pharmacol Rev 49(2):139-162. PMID:9140408.
Pickel VM, et al. "VMAT2: synaptic vesicle localization." J Comp Neurol 359(1):75-94. PMID:7542566.